Current State: vincerebio.com
vincerebio.com
Current Vincere Biosciences website
Loading current site…
01
No investor narrative.

Visitors arrive with no understanding of the raise, the ask, or why this moment matters.

02
Pipeline invisible.

VB-23 and VB-CRD buried in paragraphs. No stage gates, no milestones, no timeline.

03
Science untranslated.

USP30 inhibition for mitophagy restoration is not told in investor terms.

04
Funding unacknowledged.

$8M+ across NIH, MJFF, and Draper is not surfaced above the fold.

05
No specific ask.

Licensing? Series A? Co-development? The site does not say. So visitors do not act.

06
Design signals pre-revenue.

Off-the-shelf presentation communicates where the company has been, not where it is going.

Thescienceispeer-reviewed.
Theinvestorstoryisn’t
Notyet.
Redesign
vincerebiosciences.com
Redesign Preview
The Redesign

Vincere Biosciences: what this site could be.

Scroll through each section. Each callout shows what it communicates to investors, partners, and collaborators.

Vincere Brand Investor + Partner Ready
VB-23 IND-Enabling 2026

Restoring mitochondrial health to halt Parkinson’s progression.

Partner With Us →
01

Investor narrative in the first sentence.

No scrolling required. The visitor understands the platform, the disease, and the urgency before a single paragraph is read.

Hero · Immediate narrative clarity
$8M+
Raised to date
NIH
Funded
MJFF
Partner
IND
Enabling 2026
02

Proof before the scroll.

Four credibility signals above the fold. Funding raised, institutional backing, and next milestone before a single claim is made about the science.

Stats strip · Instant credibility
Clinical Pipeline

Two assets. Two disease areas.
One story.

Discovery
Lead Opt
IND Prep
IND Active
Phase I
Phase II
VB-23
Parkinson’s Disease
USP30 inhibition → mitophagy restoration → neuroprotection
IND-Enabling Active
VB-CRD
Cardiorenal Disease
Mitochondrial dysfunction → metabolic restoration axis
Lead Optimisation
03

Stage-gated pipeline. At a glance.

Two programs. Two disease areas. Progress bars and stage labels that show exactly where each asset is in development and what comes next.

Pipeline · Progress made visible
Mechanism of Action

Complex science,
made visible.

1
Damaged Mitochondria
Parkin/PINK1 tags dysfunctional mitochondria for clearance via mitophagy
2
VB
USP30 Blocks Clearance
VB-23 selectively inhibits USP30, the enzyme preventing damaged mitochondria from being removed
3
Mitophagy Restored
Damaged mitochondria cleared. Neuronal health protected. Disease progression halted.
04

Complex science, shown not described.

The USP30 inhibition pathway becomes a three-step visual any visitor follows in under ten seconds. Scientists see rigour. Partners see opportunity. No decoder ring required.

Mechanism · Science made accessible
Backed By

Institutional conviction
from day one.

NIH MJFF Draper Parkinson’s UK NINDS Alpha-1 Foundation LifeSci Venture Spinout.fyi
05

Institutional credibility in two seconds.

NIH. MJFF. Draper seen immediately, before any claim about the science. Social proof that reframes everything the visitor reads next.

Investor strip · Trust before claims
VB-23 enters IND-enabling studies 2026
One asset. One clear path. One conversation.
Exploring co-development and out-licensing for VB-23.
Request a Partnering Briefing →
06

One specific ask. No ambiguity.

Not a generic contact form. A milestone-tied call to action for the exact partner Vincere needs, positioned before the IND window opens.

CTA · Clarity over completeness

A full communication partner. Not a deck shop.

Three materials. One narrative. Built together so the story stays consistent whether a partner finds Vincere online, sits in a meeting, or reads the leave-behind the next morning.

Vincere Bio: Web Presence
Investor-first digital foundation
Web Presence
The investor-first website
Built for the moment before the first meeting. Designed to answer the question before it is asked.
VB-23 · Parkinson’s Platform
From Mechanism to Market: The USP30 Story
Pipeline Progress
VB-23
VB-CRD
$8M+
Raised
NIH
Funded
2026
IND
Investor Deck
The narrative that moves capital
From mechanism to market. Structured to move from pitch to partnership without losing the science.
Platform
Pipeline
The Ask
Vincere Biosciences · Confidential
One-Pager
The leave-behind that follows up for you
Platform. Pipeline. The ask. One page designed to travel between partners and live in an investor inbox.
The Unspoken Pitch

Let’s understand your story properly.

Everything above came from your public website. No brief. No conversation. The science was already there. It just needed a different translation. A 30-minute conversation with Scott is where the full story starts.